2017
DOI: 10.1097/mbc.0000000000000649
|View full text |Cite
|
Sign up to set email alerts
|

Factor XIII deficiency in south of Tunisia

Abstract: : Factor XIII deficiency is a rare autosomal recessive disorder of hemostasis characterized by a plasmatic factor XIII level less than 1% in homozygote and bleeding as of the youth. The aim of the study is to describe the clinical features and the outcome of the patients and to determine molecular characteristics. A retrospective study, was conducted on seven patients with factor XIII deficiency in the department of hematology and pediatrics, Hedi Chaker Hospital, Sfax, Tunisia during the period of 14 years (2… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2018
2018
2018
2018

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 20 publications
0
1
0
Order By: Relevance
“…If this happens before surgery, then FXIII should be replenished by infusing either fresh frozen plasma, cryoprecipitate, or recombinant FXIII [21]. In the setting of FXIII deficiency, which is a rare autosomal recessive disorder, Maaloul et al [22] found that transfusion of fresh frozen plasma into 7 such patients, on a monthly basis, prevented hemorrhagic complications, except for 1 patient who died from intracranial hemorrhage. Similarly, a recent study reported on 6 children with factor XIII-A deficiency who had received once-monthly prophylaxis with recombinant factor XIII-A: the prophylaxis was well tolerated and no anti-FXIII antibodies were detected.…”
Section: Discussionmentioning
confidence: 99%
“…If this happens before surgery, then FXIII should be replenished by infusing either fresh frozen plasma, cryoprecipitate, or recombinant FXIII [21]. In the setting of FXIII deficiency, which is a rare autosomal recessive disorder, Maaloul et al [22] found that transfusion of fresh frozen plasma into 7 such patients, on a monthly basis, prevented hemorrhagic complications, except for 1 patient who died from intracranial hemorrhage. Similarly, a recent study reported on 6 children with factor XIII-A deficiency who had received once-monthly prophylaxis with recombinant factor XIII-A: the prophylaxis was well tolerated and no anti-FXIII antibodies were detected.…”
Section: Discussionmentioning
confidence: 99%